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J PIntroduction: Advances in primary prophylaxis have resulted in improved outcomes for patients
with sickle cell anemia (SCA; i.e., hemoglobin SS- and Sβ0-thalassemia). Standard prophylactic
measures include a ﬁrst pneumococcal polysaccharide vaccine (PPV) and transcranial Doppler
ultrasound (TCD) at age 2 years. Though efﬁcacious, evidence suggests that delivery of these
interventions is suboptimal. This study reports adherence to these measures and examines
concordance across various data sources, using Registry and Surveillance for Hemoglobinopathies
project data.
Methods: Retrospective database and SCA center chart review identiﬁed children with SCA aged
24–36 months between January 1, 2004, and December 31, 2008. PPV and TCD administration were
determined through Medicaid and Children’s Health Insurance Program administrative claims data,
medical record review, and Georgia Registry of Immunization Transaction and Services. Analysis
was conducted in 2015.
Results: A total of 125 children met inclusion criteria. Forty-ﬁve (36.0%) children had
documentation of both interventions, whereas 19 (15.2%) had no documentation of either
intervention. Sixty-one (48.8%) children obtained only one intervention. Of these, more were likely
to have had PPV than TCD (77.0% vs 23.0%, respectively, po0.001). Agreement between claims
data and medical record review was moderate for PPV (κ¼0.55) and substantial for TCD (κ¼0.74).
Conclusions: No single, reliable data source for tracking standard of care for children with SCA
statewide was found. According to study data, prophylaxis measures were not universally
implemented during the surveillance period. Further research is needed to adequately track changes
over time, determine risk groups, and develop methods of evaluating important metrics.
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open access article under the CC BY-NCIntroductionSickle cell disease (SCD) is the most commongenetic disorder identiﬁed by newborn screening(NBS) in the U.S. Major causes of morbidity and
mortality in children with SCD include invasive pneumo-
coccal infection1,2 and stroke.3,4 Advances in compre-
hensive care have resulted in improved outcomes.5
Primary prevention against pneumococcal disease
includes prophylactic antibiotic therapy starting in
infancy and immunization with the pneumococcal 13-
valent conjugate vaccine (PCV) and the pneumococcal
polysaccharide vaccine (PPV).1,6,7 In 1998, the largeurnal of Preventive Medicine. Published by Elsevier Inc. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Anemia (SCA) demonstrated that chronic transfusions
prevent stroke in high-risk children with hemoglobin SS-
and Sβ0-thalassemia, that is, SCA, which is identiﬁed by
transcranial Doppler ultrasonography (TCD) screening.8
Thus, the standard of care for children with SCA includes
PPV and TCD, both initiated at age 2 years.9,10 Although
these interventions show efﬁcacy in reducing major
complications,11–17 evidence suggests that signiﬁcant
barriers limit their implementation,18–22 including access
to subspecialty care, family and provider education, and
sociodemographic factors.19
In 2011, the U.S. DHHS launched an initiative to
improve care for people with SCD, which included
the development of population-based surveillance
strategies to identify individuals living with SCD and
other hemoglobinopathies.23 In addition, Healthy People
2020 objectives include preventive health metrics for
people living with hemoglobinopathies. Seven states,
including Georgia, were funded by the Centers for Disease
Control and Prevention (CDC) and the National Heart,
Lung, and Blood Institute to develop and pilot statewide
surveillance systems through the Registry and Surveil-
lance for Hemoglobinopathies (RuSH) project.22
Using Georgia RuSH data, two metrics related to
Healthy People 2020 Blood Disorders and Blood Safety
objectives are examined:1.JulObjective 1: Increase the proportion of people with
hemoglobinopathies who receive recommended vaccines,
using the receipt of the ﬁrst dose of PPV as a metric.2. Objective 4: Increase the proportion of people with
hemoglobinopathies who receive early and continuous
screening for complications, using the initiation of
TCD screening as a metric.
This study explores the utility of using administrative
claims and statewide immunization databases to assess
adherence with preventive guidelines and contributes to
the development of quality of care metrics speciﬁc to
individuals with SCA.Methods
A subset of data from the Georgia RuSH Project that included
clinical records from Georgia’s NBS program; the comprehensive
sickle cell centers at Georgia Regents University (GRU); Grady
Health System; and Children’s Healthcare of Atlanta (CHOA); and
administrative claims data from Georgia’s Medicaid and Child-
ren’s Health Insurance Program, State Health Beneﬁt Plan, and the
Georgia Hospital Association was used to perform a retrospective
cohort study. All conﬁrmed case patients had conﬁrmatory
hemoglobin electrophoresis testing and a documented clinical
diagnosis in the medical record. Insurance claims data fromy 2016Medicaid and the Children’s Health Insurance Program were
available for 70% of the conﬁrmed case patients (2,986/4,288).1
Administrative claims data were used to identify receipt of PPV
and TCD, using speciﬁc procedural codes. In addition to the RuSH
data, the Georgia Registry of Immunization Transactions and
Services (GRITS) and medical record review from CHOA and
GRU, the same programs that provided laboratory conﬁrmation of
SCD diagnosis to the RuSH data, were used to identify receipt of
PPV and TCD. All study procedures received approval or
exemption from the relevant IRBs. The Georgia Departments of
Community Health and Public Health reviewed and approved the
data requests, ensuring data privacy safeguards were in place.
Included here were children from the RuSH data set with
hemoglobin SS- or Sβ0-thalassemia, who were aged 24–36 months
between January 1, 2004, and December 31, 2008, and had public
insurance coverage for at least 9 of 12 months. This criterion
ensured adequate claims data and eliminated children who moved
out of the state or changed health coverage. Children with a history
of stroke before age 2 years and who did not receive care at CHOA
or GRU were excluded. TCD examinations were conducted at the
site of sickle cell care, whereas PPV may have been given at the
comprehensive sickle cell center, local health department, or the
primary care provider. All data were analyzed in 2015.
The primary outcome variables were adherence to PPV immu-
nization and TCD screening, deﬁned as the proportion of children
with SCA who received their ﬁrst PPV and TCD between ages 24
and 36 months. These outcomes were selected as they both occur
between the second and third birthday, are unique to patients with
SCA, and relate directly to a Healthy People 2020 objective. TCD
screening was identiﬁed in the RuSH administrative claims data by
using Current Procedural Terminology (CPT) codes 938XX, which
represent both complete and limited TCDs. Immunization with
PPV was identiﬁed using CPT code 90732 for Pneumovax 23
administration. A child was considered to have had PPV immu-
nization if this CPT code was present in the claims data during the
period from 2 weeks before age 2 years through age 3 years, and
considered to have had TCD screening if the corresponding CPT
codes were present between the second and third birthdays.
Administration of the ﬁrst dose of PPV was documented from
GRITS. Medical record reviewers recorded clinic visit dates during
the child’s third year of life, whether or not a PPV or TCD was
documented, and the date of administration.
Descriptive statistics and outcome measures were reported.
Kappa statistics compared measures of agreement between data
sources. Three data sources were compared for PPV: adminis-
trative claims data, medical record review, and GRITS. Only the
ﬁrst two data sources were relevant to compare TCD adherence. A
κ-statistic of 0.2–0.4 was considered “fair agreement,” 0.4–0.6 was
considered “moderate agreement,” and 0.6–0.8 was considered
“substantial agreement.”23 Dependent-sample t-tests were con-
ducted to compare differences in proportions, and Mantel–
Haenszel trend tests were used to assess PPV and TCD adherence
across calendar years. A p-value ofo0.05 was considered statisti-
cally signiﬁcant. All analyses were done using SAS, version 9.3.Results
A total of 4,288 children and adults were identiﬁed
by Georgia RuSH between 2004 and 200824 with a
Table 1. Prevalence of SCD Speciﬁc Interventions
Documented by at Least One Data Source
Intervention documented at least once
between ages 2 and 3 years
n (%)
(N¼125)
PPV and TCD 45 (36.0)
PPV only 47 (37.6)
TCD only 14 (11.2)
Neither PPV nor TCD documented 19 (15.2)
Total receiving PPV 92 (73.6)
Total receiving TCD 59 (47.2)
PPV, pneumococcal polysaccharide vaccine; SCD, sickle cell disease;
TCD, transcranial Doppler ultrasonography.
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Sβ0-thalassemia. A total of 285 were aged 2–3 years, and
143 (50%) were enrolled in public insurance coverage for
at least 9 of 12 months. Eighteen children were excluded:
one had a stroke prior to age 2 years and 17 had no GRU
or CHOA medical record available. The remaining 125
children were included in this analysis. Of the 125
included children, the majority were African American
(85.6%) and classiﬁed as non-Hispanic (89.6%). The
study population was balanced with regard to gender
(47.2% male).Table 2. Prevalence of SCD-Speciﬁc Interventions by Source an
Birth year
At least one
source (n¼92)
M
CH
p-value testing across birth year 0.09
2003 (n¼36) 22 (61.1)
2004 (n¼51) 40 (78.4)
2005 (n¼38) 30 (78.9)
At least one source
(n¼59)
p-value testing across birth year 0.63
2003 (n¼36) 15 (41.7)
2004 (n¼51) 26 (51.0)
2005 (n¼38) 18 (47.4)
Note: Boldface indicates statistical signiﬁcance (po0.05). Values are n (%)
CHIP, Children’s Health Insurance Program; GRITS, Georgia Registry of Im
transcranial Doppler ultrasonography.Prevalence rates of PPV and TCD for all three data
sources are outlined in Table 1. Children were more
likely to have PPV documented than TCD in all three
data sources (92/125¼73.6% vs 59/125¼47.2%,
po0.001). Approximately one third of children had
evidence of receiving PPV and TCD, whereas 15.2%
(n¼19) had no documentation of either intervention.
Children who had only obtained one intervention
(n¼61) were more likely to have had PPV (47/
61¼77.0%) than TCD (14/61¼23.0%) (po0.001).
Trends in prevalence are outlined in Table 2. There
was no trend by birth cohort for TCD screening. For
PPV, there was no change in overall adherence based on
birth cohort using at least one data source. There was,
however, an increasing trend in the claims data as well as
documentation in GRITS.
For patients without either intervention (n¼19), nine
had inadequate follow-up, four received the interventions
outside the study window, four had inadequate docu-
mentation of the intervention timing, and one had
inadequate data to determine the reason. One child had
no reason listed for not receiving PPV and did not receive
TCD because of chronic transfusions. Of patients missing
only PPV (n¼14), the most common documented reason
was insufﬁcient or no documentation (n¼12); loss to
follow-up (n¼1); and not available at the clinic (n¼1).
Similarly, for the 47 children missing only TCD, the most
common reason was insufﬁcient documentation (n¼31);d Birth Year, 2003–2005
PPV
edicaid or
IP (n¼55)
Clinical
chart (n¼63) GRITS (n¼69)
o0.01 0.06 0.01
7 (19.4) 12 (33.3) 14 (38.9)
27 (52.9) 30 (58.8) 29 (56.9)
21 (55.3) 21 (55.3) 26 (68.4)
TCD
Medicaid or CHIP
(n¼49) Clinical chart (n¼53)
0.32 0.23
11 (30.6) 12 (33.3)
22 (43.1) 23 (45.1)
16 (42.1) 18 (47.4)
unless otherwise indicated.
munization Transactions and Services; SCD, sickle cell disease; TCD,
www.ajpmonline.org
Table 3. Comparison of PPV and TCD Documentation Status by Data Source (N¼125)
PPV TCD
Documentation
Documented in
Medicaid or
CHIP, n (%)
Not documented
in Medicaid or
CHIP, n (%)
Documented in
Medicaid or
CHIP, n (%)
Not documented
in Medicaid or
CHIP, n (%)
Documented in clinical chart 45 (36.0) 18 (14.4) 43 (34.4) 10 (8.0)
Not documented in clinical chart 10 (8.0) 52 (41.6) 6 (4.8) 66 (52.8)
Documented in
GRITS, n (%)
Not documented
in GRITS, n (%)
Documented in Medicaid or CHIP 45 (36.0) 10 (8.0)
Not documented in Medicaid or
CHIP
24 (19.2) 46 (36.8)
Documented in clinical chart 43 (34.4) 20 (16.0)
Not documented in clinical chart 26 (20.8) 36 (28.8)
CHIP, Children’s Health Insurance Program; GRITS, Georgia Registry of Immunization Transactions and Services; PPV, pneumococcal polysaccharide
vaccine; TCD, transcranial Doppler ultrasonography.
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loss to follow-up (n¼2); and poor adherence with clinic
visits (n¼1).
Among children who had PPV documented by any of
the three data sources (n¼92), GRITS was identiﬁed as
the most inclusive data source (69/92¼75.0%) compared
with medical record review (63/92¼68.5%) and admin-
istrative claims (55/92¼59.8%). Among children who had
TCD documented by either of the two data sources
(n¼59), medical record review (53/59¼89.8%) and admin-
istrative claims (49/59¼83.1%) were similarly useful.
Table 3 shows the percentage of children who had an
intervention documented by data source. The level of
agreement (Table 4) between administrative claims data
and medical record review was moderate for PPV
(κ¼0.55) and substantial for TCD (κ¼0.74). Further-
more, agreement with GRITS was moderate for admin-
istrative claims (κ¼0.46) and fair for medical record
review (κ¼0.26). Twenty-three children were identiﬁed
for whom no administration of PPV was recorded inTable 4. Measures of Agreement Between Data Sources for Do
Prophylactic measure Data source compariso
PPV Medicaid and CHIP compared to c
Medicaid and CHIP compared to G
Clinical chart compared to GRITS
TCD Medicaid and CHIP compared to c
CHIP, Children’s Health Insurance Program; GRITS, Georgia Registry of Immu
vaccine; TCD, transcranial Doppler ultrasonography.
July 2016GRITS; however, a claim was processed or documenta-
tion was found in the medical record.Discussion
During the 5-year study period, ﬁndings suggest that the
standard of care was suboptimal, particularly for TCD
screening, and that discordance existed between data
sources. Only 36.0% of children had documentation of
both PPV and TCD, and 15.2% of children received
neither intervention. These ﬁndings support previous
studies18–22 demonstrating suboptimal adherence with
primary SCD prevention in children.
The PPV and pneumococcal prevention strategies
have decreased bacterial infections.11–13 Despite this
decline, few studies have monitored adherence to vacci-
nation rates.5,21,22 This study found 73.6% of children
received their ﬁrst PPV at age 2 years. A case-control
study21 of pneumococcal vaccine adherence (PCV7 and
PPV) in Michigan using Medicaid claims data betweencumentation of PPV and TCD
ns Overall agreement, % Kappa
linical chart 77.6 0.552
RITS 72.8 0.463
63.2 0.263
linical chart 87.2 0.735
nization Transactions and Services; PPV, pneumococcal polysaccharide
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received at least one pneumococcal vaccine by age 3
months and 73% had three documented by age 24
months. These rates are similar to the 73.6% observed
in this study. Lower rates of PPV adherence were seen in
a retrospective cohort of Wisconsin Medicaid claims
conducted between 2003 and 2007, with only 49.8% of
children aged 2–18 years adherent with PPV vaccina-
tion.22 Taken together, studies using claims data ﬁnd
approximately 25%–50% of children with SCD have not
received timely vaccination against invasive pneumo-
coccal disease. The proportion of children receiving
PCV-23 by age 3 years was higher among children in a
single-center cohort (82.4% in 1994 and 100% in 2006),
likely representing the difference between single-center
experiences and universal surveillance data.5 In this
study, PPV rates did increase over time based on claims
data and GRITS, likely reﬂecting the increased efforts of
CDC during this time to create immunization informa-
tion systems as well as improved coding.
In this study, adherence with TCD (47.2%) was lower
than for PPV, possibly reﬂecting poor initial adoption of
the relatively newer TCD screening guidelines.8,9 Others
have shown improvement in TCD implementation over
time since the Stroke Prevention Trial in SCA in
1998.18,19 In a study18 of the Kaiser Permanente Medical
Care Program, screening rates were 1.8 per 100 person-
years prior to 1998, increasing to 5.0 per 100 person-
years in 1998–1999 and even further to 11.4 per 100
person-years following 1999. Similarly, Tennessee Med-
icaid claims data showed the incidence of TCD screening
to be 2.5% in 1997 and as high as 68.3% in 2008.19
Another rationale for increased screening rates is the
availability of oral iron chelators, which provide an
alternative to deferoxamine and shift the risk–beneﬁt of
chronic transfusions. The Georgia population may be
unique in that it has a relatively large number of rural
patients who receive care at public health clinics where
screening was not available onsite until after 2009. This
likely accounts for the low TCD screening rates; adher-
ence might be better in a more modern cohort.25 This
highlights the complexity in delivering technology-based
interventions such as TCD in rural settings. Efforts
directed at understanding and addressing barriers to
receiving the standard of care that incorporate all stake-
holders are needed.
Because some of the guidelines for preventive care of
patients with SCD are genotype speciﬁc, the use of a
statewide data system for the surveillance of SCD has an
advantage over general health service data sources for
measuring quality of care. The RuSH surveillance system
in Georgia contains laboratory-conﬁrmed SCD geno-
types for 4,288 individuals that are matched to theadministrative data sources. Identiﬁcation of SCD based
on ICD-9-CM coding contained in administrative data
sets alone does not accurately differentiate SCD geno-
types and would not identify individuals who should be
receiving particular preventive screenings. Even with
ICD-10 coding, it will not be possible to distinguish
between all SCD genotypes. State public health depart-
ments are strategically positioned to create longitudinal
surveillance systems for children with SCD and other
genetic disorders, because they typically administer and
have access to birth records, NBS data, and immuniza-
tion registries. Most state public health departments can
also link these data to Medicaid and hospital admin-
istrative data under their public health authority. Several
states, including North Carolina, California, and Mich-
igan, have developed NBS follow-up systems.26
Some discordance between the data sources used to
measure receipt of the preventive interventions was
found. Concordance between administrative claims data
and medical record review was substantial for TCD
(κ¼0.74) and moderate for PPV (κ¼0.55). Validation
data from the Tennessee study found procedure claims
for TCD (using similar codes in addition to CPT codes
76506 for ultrasound head and 76536 for ultrasound soft
tissues of head and neck) to be 90.5% sensitive with a
positive predictive value of 100% compared to medical
records.19 Although the κ-statistics are adequate, in
neither case was there 100% concordance. It was
hypothesized that the majority of discordance would
come from a positive claim that was not documented in
the medical record; nevertheless, this was not found.
Both the medical records and administrative claims had
an equal number of missing data; however, GRITS
provided an additional source of comprehensive infor-
mation to document PPV.
The higher concordance rate for TCD compared with
PPV is likely because TCD screening was easier to
identify in medical records as it is usually conducted in
the same location as specialty patient care. By contrast,
immunizations for children followed in the specialty
clinics were often administered at a different site, such
as the primary care physician’s ofﬁce, and therefore the
status in the medical record often lacked detail. Addi-
tionally, if the vaccination was provided at a health
department clinic, a Medicaid/Children’s Health Insur-
ance Program claim was unlikely to be generated as
vaccines are provided free of charge to publicly insured
children. For this reason, many providers rely on the
statewide GRITS data system for immunization track-
ing. Although these barriers to tracking interventions
might be unique to the state of Georgia, they further
highlight the need for general, centralized tracking
mechanisms.www.ajpmonline.org
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for measuring adherence with PPV and TCD in SCD; use
of all three data sets provided the most robust data. State-
based immunization registries may offer the best doc-
umentation of immunization adherence, even for special
populations. Similarly, administrative health insurance
data such as Medicaid claims can be used to appropriately
identify receipt of a TCD screen. Moreover, in order to
precisely measure both interventions, these data sources
require linkage, at the individual level, to a surveillance
system or patient registry containing SCD genotypes.
These population-based prevention metrics for SCD
are also applicable to health systems, clinics, and indi-
vidual practices as the U.S. healthcare system moves to
population-based ﬁnancing models like accountable care
organizations, global payment structures, and additional
value-based purchasing models. Many providers are
developing patient registries, modifying electronic health
records to include relevant indicators of risk, and
utilizing patient navigators to reach out to patients to
reduce access barriers and improve the quality of care.27
Developing and testing care metrics is the ﬁrst step in
improving quality of care for individuals with chronic
diseases like SCD.
Limitations
This study is limited in its retrospective nature and the
assumption that charges and other documentation of an
intervention were accurate. The data are also limited in
that only medical records at specialty providers were
included in the review; adherence may be different for
patients followed elsewhere or if primary care medical
records were also available for review. The use of health
information exchanges may provide more transparent
sharing of patient data between primary care and sub-
specialty providers. Children who did not have public
insurance for 9 of 12 months were excluded to create a
continuously insured cohort; inclusion of children who
lack continuous coverage would likely reduce screening
rates. Study data may not be representative of all SCD
populations such as more-urban populations, those pri-
vately insured, or in publicly insured cohorts with annual
eligibility periods rather than 6-month periods as was the
case in Georgia. PPV or TCD adherence rates beyond age
3 years were not measured. Lastly, patient and provider
factors that might inﬂuence adherence were not assessed.
Conclusions
Using the Georgia RuSH population-based surveillance
database, including administrative claims data, GRITS,
and medical record review, adherence with PPV immu-
nization and TCD screening among children aged 2 yearsJuly 2016with SCD were assessed between 2004 and 2008. Find-
ings suggest adherence was not universal and a signiﬁ-
cant portion of patients did not receive these important
interventions during that period. Although no single,
comprehensive data source for documenting population-
based care metrics was found, state-based surveillance
systems that link at-risk children through NBS programs
with administrative records or immunization registries to
document clinical events can be used to monitor pre-
ventive care for young children with SCD. Immunization
registries are the best source for documenting pneumo-
coccal vaccination, and administrative claims data are
similar to chart review in monitoring TCD use over time.
Both of these metrics may also be of use to providers
developing their own quality-monitoring systems within
their practices.Publication of this article was supported by the Centers for
Disease Control and Prevention.
The authors would like to acknowledge the additional
Georgia Registry and Surveillance for Hemoglobinopathies
(RuSH) team members for their contributions to securing the
surveillance data that made this study and paper possible:
James Eckman, MD, and Eldrida Randall, Emory University,
GA, Comprehensive Sickle Cell Center at Grady Health
System, and JoAnn Beasley, RN, Georgia Department of Public
Health, as well as the Public Health Research, Epidemiology,
and Surveillance for Hemoglobinopthies (PHRESH) team
members who secured chart review and Georgia Immunization
Registry data for this paper: Rodney Theodore, MPH, and
Yuritzi Jones, BS, Children’s Health Care of Atlanta and Todd
Grifﬁn, MPH, Georgia Department of Public Health.
Surveillance data collection was supported by Cooperative
Agreements DD09-909 and DD10-1017 (RuSH) from CDC.
The public health research was supported by Cooperative
Agreement 5U50DD001010 (PHRESH) from CDC. Data
collection at Children’s Healthcare of Atlanta was supported
by a grant from the Abraham J. & Phyllis Katz Foundation.
The content of this paper is solely the responsibility of the
authors and does not necessarily represent the ofﬁcial views of
the CDC.
No ﬁnancial disclosures were reported by the authors of
this paper.References
1. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin
in children with sickle cell anemia. A randomized trial. N Engl J Med.
1986;314(25):1593–1599. http://dx.doi.org/10.1056/NEJM1986061931
42501.
2. Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle
hemoglobinopathies. J Pediatr. 1986;109(4):579–585. http://dx.doi.org/
10.1016/S0022-3476(86)80216-5.
Neunert et al / Am J Prev Med 2016;51(1S1):S24–S30S303. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular
accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):
288–294.
4. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. Sickle cell
disease: the neurological complications. Ann Neurol. 2002;51(5):
543–552. http://dx.doi.org/10.1002/ana.10192.
5. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival
of children and adolescents with sickle cell disease. Blood. 2010;115
(17):3447–3452. http://dx.doi.org/10.1182/blood-2009-07-233700.
6. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR.
Prevention of pneumococcal infection in children with homozygous
sickle cell disease. Br Med J (Clin Res Ed). 1984;288(6430):1567–1570.
http://dx.doi.org/10.1136/bmj.288.6430.1567.
7. Bennett N, Pilishvili T, Whitney C, Moore M, Gierke R, Harris A. Use
of 13-valent pneumococcal conjugate vaccine and 23-valent pneumo-
coccal polysaccharide vaccine among children aged 6–18 years with
immunocompromising conditions: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Morb Mortal
Wkly Rep. 2013;62(25):521–524.
8. Adams RJ, McKie VC, Hsu L, et al. Prevention of a ﬁrst stroke by
transfusions in children with sickle cell anemia and abnormal results
on transcranial Doppler ultrasonography. N Engl J Med. 1998;339
(1):5–11. http://dx.doi.org/10.1056/NEJM199807023390102.
9. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of
sickle cell disease: summary of the 2014 evidence-based report by
expert panel members. JAMA. 2014;312(10):1033–1048. http://dx.doi.
org/10.1001/jama.2014.10517.
10. American Academy of Pediatrics Committee on Infectious D. Recom-
mendations for the prevention of Streptococcus pneumoniae infections
in infants and children: use of 13-valent pneumococcal conjugate
vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
Pediatrics. 2010;126(1):186–190. http://dx.doi.org/10.1542/
peds.2010-1280.
11. Payne AB, Link-Gelles R, Azonobi I, et al. Invasive pneumococcal
disease among children with and without sickle cell disease in the
United States, 1998 to 2009. Pediatr Infect Dis J. 2013;32(12):1308–
1312. http://dx.doi.org/10.1097/INF.0b013e3182a11808.
12. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive
pneumococcal disease among individuals with sickle cell disease before
and after the introduction of the pneumococcal conjugate vaccine. Clin
Infect Dis. 2007;44(11):1428–1433. http://dx.doi.org/10.1086/516781.
13. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. Hospitalization for
invasive pneumococcal disease in a national sample of children with
sickle cell disease before and after PCV7 licensure. Pediatr Blood
Cancer. 2012;58(6):945–949. http://dx.doi.org/10.1002/pbc.23259.
14. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in
incidence rates of hospitalization for stroke in children with sickle celldisease. Pediatr Blood Cancer. 2013;60(5):823–827. http://dx.doi.org/
10.1002/pbc.24392.
15. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in
Californian children with sickle cell disease. Blood. 2004;104(2):336–
339. http://dx.doi.org/10.1182/blood-2004-02-0636.
16. Lehman LL, Fullerton HJ. Changing ethnic disparity in ischemic stroke
mortality in US children after the STOP trial. JAMA Pediatr. 2013;167
(8):754–758. http://dx.doi.org/10.1001/jamapediatrics.2013.89.
17. Enninful-Eghan H, Moore RH, Ichord R, Smith-Whitley K, Kwiat-
kowski JL. Transcranial Doppler ultrasonography and prophylactic
transfusion program is effective in preventing overt stroke in children
with sickle cell disease. J Pediatr. 2010;157(3):479–484. http://dx.doi.
org/10.1016/j.jpeds.2010.03.007.
18. Armstrong-Wells J, Grimes B, Sidney S, et al. Utilization of TCD
screening for primary stroke prevention in children with sickle cell
disease. Neurology. 2009;72(15):1316–1321. http://dx.doi.org/10.1212/
WNL.0b013e3181a110da.
19. EckrichMJ, WangWC, Yang E, et al. Adherence to transcranial Doppler
screening guidelines among children with sickle cell disease. Pediatr
Blood Cancer. 2013;60(2):270–274. http://dx.doi.org/10.1002/pbc.24240.
20. Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical
assessment of transcranial doppler screening rates in a large pediatric
sickle cell center: opportunities to improve healthcare quality. Pediatr
Blood Cancer. 2008;51(5):647–651. http://dx.doi.org/10.1002/pbc.21677.
21. Nero AC, Akuete K, Reeves SL, Dombkowski KJ. Pneumococcal vacci-
nation rates in children with sickle cell disease. J Public HealthManag Pract.
2014;20(6):587–590. http://dx.doi.org/10.1097/PHH.0000000000000034.
22. Beverung LM, Brousseau D, Hoffmann RG, Yan K, Panepinto JA.
Ambulatory quality indicators to prevent infection in sickle cell disease.
Am J Hematol. 2014;89(3):256–260. http://dx.doi.org/10.1002/ajh.23627.
23. Viera AJ, Garrett JM. Understanding interobserver agreement: the
kappa statistic. Fam Med. 2005;37(5):360–363.
24. Hulihan MM, Feuchtbaum L, Jordan L, et al. State-based surveillance
for selected hemoglobinopathies. Genet Med. 2015;17(2):125–130.
http://dx.doi.org/10.1038/gim.2014.81.
25. Hussain S, Nichols F, Bowman L, Xu H, Neunert C. Implementation of
transcranial Doppler ultrasonography screening and primary stroke
prevention in urban and rural sickle cell disease populations. Pediatr Blood
Cancer. 2015;62(2):219–223. http://dx.doi.org/10.1002/pbc.25306.
26. Grigorescu V, Kleyn MJ, Korzeniewski SJ, Young WI, Whitten-
Shurney W. Newborn screening follow-up within the lifespan context:
Michigan’s experience. Am J Prev Med. 2010;38(4 suppl):S522–S527.
http://dx.doi.org/10.1016/j.amepre.2010.01.002.
27. Sobota AE, Kavanagh PL, Adams WG, McClure E, Farrell D,
Sprinz PG. Improvement in inﬂuenza vaccination rates in a pediatric
sickle cell disease clinic. Pediatr Blood Cancer. 2015;62(4):654–657.
http://dx.doi.org/10.1002/pbc.25390.www.ajpmonline.org
